Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes.
von Eynatten
Maximilian
M
Schneider
Jochen G
JG
Hadziselimovic
Senad
S
Hamann
Andreas
A
Bierhaus
Angelika
A
Nawroth
Peter P
PP
Dugi
Klaus A
KA
D052242:Adiponectin; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000069059:Atorvastatin; D002097:C-Reactive Protein / Q000378:metabolism; D016207:Cytokines / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000276:immunology*; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006729:Hormones, Ectopic / Q000097:blood; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D020738:Leptin / Q000097:blood; D008297:Male; D010919:Placebos; D011758:Pyrroles / Q000627:therapeutic use*; D052243:Resistin
D052242:Adiponectin; D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D006538:Heptanoic Acids; D006729:Hormones, Ectopic; D036341:Intercellular Signaling Peptides and Proteins; D020738:Leptin; D010919:Placebos; D011758:Pyrroles; C499624:RETN protein, human; D052243:Resistin; D002097:C-Reactive Protein; D000069059:Atorvastatin